GlassScriptPhysician profile
Camille M Pousson
NPI 1144265653
$1,565.35
in general payments reported to CMS, 2019-2025
12 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $51.61 · 2021: $14.63 · 2022: $123 · 2023: $217 · 2024: $548 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.09 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $498.97 | 2023-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.45 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $194.12 | 2019-2025 | Ingrezza |
| Abbvie INC. | $165.11 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $162.49 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $89.39 | 2019-2024 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $42.01 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $38.00 | 2019-2025 | Fanapt |
| Indivior INC. | $37.35 | 2019-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $33.64 | 2023-2024 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $17.82 | 2019 | |
| Allergan, INC. | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Pousson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.